TABLE 2.
Results of pathway enrichment analysis (Top 10 terms of each category are listed).
| Category | Pathways | p Values | Genes |
|---|---|---|---|
| BioCarta | IL-2 Receptor Beta Chain in T cell Activation Homo sapiens h il2rbPathway | 0.0138338080227847 | CCNA1; FASLG |
| FOSB gene expression and drug abuse Homo sapiens h fosbPathway | 0.0181189156620487 | GRIA2 | |
| BTG family proteins and cell cycle regulation Homo sapiens h btg2Pathway | 0.0323806409307269 | HOXB9 | |
| E2F1 Destruction Pathway Homo sapiens h skp2e2fPathway | 0.0359140308301434 | CCNA1 | |
| The 4-1BB-dependent immune response Homo sapiens h 41bbPathway | 0.04643802536608 | TNFSF9 | |
| Stress Induction of HSP Regulation Homo sapiens h hsp27Pathway | 0.0499207817226997 | FASLG | |
| Fibrinolysis Pathway Homo sapiens h fibrinolysisPathway | 0.0533909917466193 | F13A1 | |
| PTEN dependent cell cycle arrest and apoptosis Homo sapiens h ptenPathway | 0.0533909917466193 | FASLG | |
| Role of nicotinic acetylcholine receptors in the regulation of apoptosis Homo sapiens h achPathway | 0.0602939507842242 | FASLG | |
| AKT Signaling Pathway Homo sapiens h aktPathway | 0.063726788409155 | FASLG | |
| KEGG | Hematopoietic cell lineage | 0.0004732170383932 | IL11; GP9; ITGB3; IL1R2 |
| Cytokine-cytokine receptor interaction | 0.0007276577841539 | IL11; IL1R2; TNFSF9; FASLG; CXCL5; PF4 | |
| Platelet activation | 0.0011012083145201 | GP9; ARHGEF12; VWF; ITGB3 | |
| Complement and coagulation cascades | 0.0037189127027277 | VWF; F13A1; CLU | |
| ECM-receptor interaction | 0.0040997308534813 | GP9; VWF; ITGB3 | |
| Rheumatoid arthritis | 0.0047855217302221 | IL11; MMP1; CXCL5 | |
| Human papillomavirus infection | 0.0072251758023511 | CCNA1; VWF; ITGB3; FASLG; OASL | |
| Tyrosine metabolism | 0.0076403289160953 | HGD; TAT | |
| Long-term depression | 0.0202928568764024 | GNAZ; GRIA2 | |
| Phenylalanine, tyrosine and tryptophan biosynthesis | 0.0217036627474641 | TAT | |
| Reactome | Formation of Fibrin Clot (Clotting Cascade) Homo sapiens R-HSA-140877 | 0.0000121946761974 | GP9; VWF; F13A1; PF4 |
| Platelet degranulation Homo sapiens R-HSA-114608 | 0.0000409918050425 | VWF; ITGB3; F13A1; CLU; PF4 | |
| Response to elevated platelet cytosolic Ca2+ Homo sapiens R-HSA-76005 | 0.0000512285968754 | VWF; ITGB3; F13A1; CLU; PF4 | |
| Platelet activation, signaling and aggregation Homo sapiens R-HSA-76002 | 0.0003237079245238 | GP9; VWF; ITGB3; F13A1; CLU; PF4 | |
| Platelet Aggregation (Plug Formation) Homo sapiens R-HSA-76009 | 0.0003315631895907 | GP9; VWF; ITGB3 | |
| MAP2K and MAPK activation Homo sapiens R-HSA-5674135 | 0.0003590424319980 | CNKSR1; VWF; ITGB3 | |
| GP1b-IX-V activation signalling Homo sapiens R-HSA-430116 | 0.0005802192831152 | GP9; VWF | |
| Phenylalanine and tyrosine catabolism Homo sapiens R-HSA-71182 | 0.0007074828428562 | HGD; TAT | |
| Hemostasis Homo sapiens R-HSA-109582 | 0.0008904420942705 | GP9; VWF; MMP1; ITGB3; KIF25; F13A1; CLU; PF4 | |
| Platelet Adhesion to exposed collagen Homo sapiens R-HSA-75892 | 0.0009986092713926 | GP9; VWF | |
| WikiPathway | SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039 | 0.0018102890593125 | TFAP2A; CXCL5; PF4 |
| Corticotropin-releasing hormone signaling pathway WP2355 | 0.0047855217302221 | TFAP2A; CRHBP; GNAZ | |
| Matrix Metalloproteinases WP129 | 0.0053503916965906 | MMP1; MMP10 | |
| 22q11.2 copy number variation syndrome WP4657 | 0.0122380560135725 | GP9; VWF; RORC | |
| Hepatitis C and Hepatocellular Carcinoma WP3646 | 0.0138338080227847 | MMP1; FASLG | |
| Ectoderm Differentiation WP2858 | 0.0140671577677321 | TFAP2A; LHX1; RGMA | |
| Netrin-UNC5B signaling pathway WP4747 | 0.0154892283448947 | ARHGEF12; RGMA | |
| Male infertility WP4673 | 0.0163380926838308 | CCNA1; FASLG; CLU | |
| Hematopoietic Stem Cell Differentiation WP2849 | 0.0172253089338917 | GP9; ITGB3 | |
| IL-18 signaling pathway WP4754 | 0.0175080436385218 | CETP; MMP1; FASLG; MYH7 |